Product catalog
contact us

    KCI BioTech (Suzhou) Inc.
    Tel：0512-69998806
    Ministry of Commerce：0512-69998806-8012
    BD：
    East and South China：Ms. Gu 15378638068
    North China, East China：Mr. Han 18914988667
    Central and Western regions: Ms. Xiang 15828112963
    Project Management Department：0512-69998806-8022
    Tumor business：0512-69998806-8058
    Non tumor business：0512-69998806-8026
    Pathogenic microorganism business：0512-69998806-8037
    Integrated Service Platform：0512-69998806-8022
    Address: Building A2, Xinyang Industrial Park, No. 8 Yanghua Road, Suzhou Industrial Park

Key models for the development of atrial fibrillation drugs

Atrial fibrillation is a common rapid arrhythmia, occurring in 1% of people over the age of 60, and the incidence increases exponentially with age. The occurrence of atrial fibrillation is related to age and underlying disease type, and hypertension is the cardiovascular disease that is most prone to developing atrial fibrillation. Patients with concomitant atrial fibrillation have a significantly increased risk of developing embolic complications.
Previous:Myocarditis
Next:Ventricular tachycardia（VT）